ES2534430T3 - Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN - Google Patents

Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN Download PDF

Info

Publication number
ES2534430T3
ES2534430T3 ES07800215.1T ES07800215T ES2534430T3 ES 2534430 T3 ES2534430 T3 ES 2534430T3 ES 07800215 T ES07800215 T ES 07800215T ES 2534430 T3 ES2534430 T3 ES 2534430T3
Authority
ES
Spain
Prior art keywords
cancer
disease
egfr
growth factor
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07800215.1T
Other languages
English (en)
Inventor
Peter Leedman
Keith Giles
Rebecca Jane Webster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39135409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2534430(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2006904662A external-priority patent/AU2006904662A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Application granted granted Critical
Publication of ES2534430T3 publication Critical patent/ES2534430T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

Un agente que comprende un miARN capaz de interaccionar con una secuencia expuesta en una cualquiera de las SEC ID Nº 31 a 36 presente en la región no traducida (UTR) 3' del receptor del factor de crecimiento epidérmico (EGFR) o una molécula efectora posterior del mismo, para su uso en el tratamiento de una enfermedad o un trastorno seleccionados entre enfermedad renal, enfermedad pulmonar, enfermedad cardiaca, enfermedad cutánea, infección, cáncer de pulmón, cáncer gastrointestinal, glioblastoma, cáncer cervical, cáncer de ovario, cáncer de vejiga, cáncer de mama, cáncer cerebral, cáncer de próstata, cáncer de colon, cáncer colorrectal, carcinoma endometrial, cáncer esofágico y cáncer de cabeza y cuello.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
    imagen2
ES07800215.1T 2006-08-28 2007-08-28 Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN Active ES2534430T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2006904662P 2006-08-28
AU2006904662A AU2006904662A0 (en) 2006-08-28 miRNA and uses thereof
AU2007900558A AU2007900558A0 (en) 2007-02-06 miRNA and uses thereof
AU2007900558P 2007-02-06
PCT/AU2007/001247 WO2008025073A1 (en) 2006-08-28 2007-08-28 Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna

Publications (1)

Publication Number Publication Date
ES2534430T3 true ES2534430T3 (es) 2015-04-22

Family

ID=39135409

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07800215.1T Active ES2534430T3 (es) 2006-08-28 2007-08-28 Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN

Country Status (5)

Country Link
US (1) US8673872B2 (es)
EP (1) EP2061482B1 (es)
DK (1) DK2061482T3 (es)
ES (1) ES2534430T3 (es)
WO (1) WO2008025073A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101475984A (zh) * 2008-12-15 2009-07-08 江苏命码生物科技有限公司 一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒
DK2414521T3 (en) * 2009-03-31 2017-01-30 Massachusetts Gen Hospital Regulation of miR-33 microRNAs in the treatment of cholesterol-related diseases
WO2010129791A1 (en) 2009-05-06 2010-11-11 University Of Medicine And Dentistry Of New Jersey Rna targeting in alpha-synucleinopathies
CA2781571A1 (en) * 2009-11-24 2011-06-03 The University Of Western Australia Modulation of epidermal growth factor receptor ligands
US20130059906A1 (en) * 2010-02-17 2013-03-07 The Board Of Regents Of The University Of Texas System Methods and compositions for influencing tumors using microrna-185 as a tumor suppressor
JP2011188849A (ja) * 2010-02-18 2011-09-29 Okayama Univ 抗腫瘍効果を有するｍｉＲ−７発現プラスミド
CA2804599C (en) 2010-07-06 2023-01-31 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
SG11202007652UA (en) 2018-02-21 2020-09-29 Bristol Myers Squibb Co Camk2d antisense oligonucleotides and uses thereof
CN109239030A (zh) * 2018-08-10 2019-01-18 北京莱尔生物医药科技有限公司 一种检测循环肿瘤细胞her2不同位点和er、pr的试剂盒及应用
CN114908089B (zh) * 2021-02-08 2024-03-15 上海细胞治疗集团有限公司 3’utr的构建方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ483599A0 (en) * 1999-12-23 2000-02-03 University Of Western Australia, The Mrna binding motif
WO2002081492A1 (en) 2001-04-04 2002-10-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human gene critical to fertility
DE10100127A1 (de) * 2001-01-03 2002-10-02 Henkel Kgaa Verfahren zur Bestimmung der Homeostase der Haut
WO2003070912A2 (en) * 2001-06-06 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1592791A2 (en) * 2003-02-10 2005-11-09 National Institute of Advanced Industrial Science and Technology Regulation of gene expression by dna interference
CA2533701A1 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7345142B2 (en) 2004-01-27 2008-03-18 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease
US20050221354A1 (en) 2004-02-18 2005-10-06 Wyeth Nucleic acid arrays for monitoring expression profiles of drug target genes
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
EP2592155B2 (en) * 2004-06-04 2019-09-11 Genentech, Inc. EGFR mutations
EP2338994B1 (en) * 2004-09-02 2014-03-19 Yale University Regulation of oncogenes by microRNAs
DK2302055T3 (da) * 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler

Also Published As

Publication number Publication date
US20100016411A1 (en) 2010-01-21
EP2061482B1 (en) 2015-01-07
US8673872B2 (en) 2014-03-18
DK2061482T3 (en) 2015-04-20
WO2008025073A1 (en) 2008-03-06
EP2061482A4 (en) 2010-12-08
EP2061482A1 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
ES2534430T3 (es) Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN
WO2008153933A3 (en) Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
AR070865A1 (es) Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso
ATE527552T1 (de) Mr-darstellungsverfahren zur diskriminierung zwischen gesundem und tumorgewebe
MY183404A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
DOP2012000291A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer de mama
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
PH12018502549A1 (en) Pharmaceutical combinations
EP1898803A4 (en) MOLECULAR / GENETIC ABERRATIONS DETECTED IN THE SURGICAL MARGINS OF A REPRESENTED PANCREATIC CANCER REPRESENTING A NEOPLASTIC DISEASE CORRESPONDING TO THE EVOLUTION OF DISEASE
TN2011000240A1 (en) Hsp90 inhibitors for therapeutic treatment
Kim et al. Macrophage-targeted indocyanine green-neomannosyl human serum albumin for intraoperative sentinel lymph node mapping in porcine esophagus
ES2491565T3 (es) Agente de transfección
BRPI0510062A (pt) derivados de antraciclina
ATE530668T1 (de) Verfahren und kits zur brustkrebsprognose
AR099036A1 (es) Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticáncer con gefitinib
RU2015127037A (ru) Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения
Hung et al. Powering tumor metastasis with recycled fuel
CR10486A (es) Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico
Azzolin Role of TAZ in cancer stem cells and Wnt signaling